the aid library

LIST OPTIONS

Filter

3682

CONSENSUS DOCUMENT FOR MANAGEMENT OF ESOPHAGEAL CANCER

Indian Council of Medical Research (ICMR) (2017) C1

Prepared as an outcome of ICMR Subcommittee on Esophageal Cancer | This consensus document on management of esophageal cancers summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It a... more

Download (206)

View PDF (451)

CONSENSUS DOCUMENT FOR MANAGEMENT OF GALLBLADDER CANCER

Indian Council of Medical Research (ICMR) (2014) C1

Prepared as an outcome of ICMR Subcommittee on Gastric Cancer | This consensus document on Management of Gallbladder cancers summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also ... more

Download (232)

View PDF (412)

CONSENSUS DOCUMENT FOR MANAGEMENT OF GASTRIC CANCER

Indian Council of Medical Research (ICMR) (2014) C1

Full document available: https://www.icmr.nic.in/sites/default/files/guidelines/Gastric%20Cancer%20Final%20pdf%20for%20farrow_0.pdf | Prepared as an outcome of ICMR Subcommittee on Gastric Cancer | Coordinated by Division of Non Communicable Diseases | This Consensus Document on Management of Gastri... more

Download (257)

View PDF (275)

Consensus Document for Management of Larynx and Hypopharynx Cancers

Indian Council of Medical Research (ICMR) (2017) C1

Prepared as an outcome of ICMR Subcommittee on Larynx & Hypopharynx Cancers | This consensus document on management of larynx and hypopharynx cancers summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and re... more

Download (210)

View PDF (270)

CONSENSUS DOCUMENT FOR MANAGEMENT OF Multiple Myelo

Indian Council of Medical Research (ICMR) (2017) C1

Prepared as an outcome of ICMR Subcommittee on Multiple Myeloma | This consensus document on management of multiple myeloma summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also i... more

Download (227)

View PDF (290)

CONSENSUS DOCUMENT FOR MANAGEMENT OF Non Hodgkin’s Lymphoma (High Grade)

Indian Council of Medical Research (ICMR) (2016) C1

Prepared as an outcome of ICMR Subcommittee on Non Hodgkin’s Lymphoma (High Grade) | This consensus document on management of non- hodgkin’s lymphoma – high grade summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molec... more

Download (247)

View PDF (260)

CONSENSUS DOCUMENT FOR MANAGEMENT OF SOFT TISSUE SARCOMA AND OSTEOSARCOMA

Indian Council of Medical Research (ICMR) (2016) C1

Prepared as an outcome of ICMR Subcommittee on Soft Tissue Sarcoma and Osteosarcoma | This consensus document on Management of Soft Tissue Sarcoma and Osteosarcoma summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular ... more

Download (237)

View PDF (254)

CONSENSUS DOCUMENT FOR MANAGEMENT OF TONGUE CANCER

Indian Consensus of Medical Research (2014) C1

Prepared as an outcome of ICMR Subcommittee on Tongue Cancer | This Consensus Document on Management of Tongue Cancers summarizes the modalities of treatment including the site-specific anti-cancer therapies, supportive and palliative care and molecular markers and research questions. It also interw... more

Download (137)

View PDF (112)

Understanding PTSD Treatment (Guide)

National Center for PTSD U.S. Department of Veterans Affairs (2011) C2

This guide covers: Treatment That Works; Myths About Treatment; Success Stories; Resources | Do you or a loved one have PTSD? There is no need to suffer. Treatment works. If you have PTSD—posttraumatic stress disorder — you don’t have to suffer. There are good treatments that can help. This b... more

External Link

Sangath

(2019) CC

Sangath is a non-governmental, not-for-profit organisation committed to improving health across the life span by empowering existing community resources to provide appropriate physical, psychological and social therapies. Its primary focus areas include child development, adolescent and youth health... more

Download (258)

View PDF (463)

"Heile Welt" Podcast
recommended

Pia Sophie Schüler; Madeleine Sittner (2019) C1

Medizin in Deutschland – alles heile Welt?! Könnte man schnell denken, wenn man im Studium nur Krankheiten und Therapiekonzepte lernt. Wir sind uns aber sicher, Medizin ist mehr und wollen mit “Heile Welt” den Kontext bieten. “Heile Welt” ist euer Podcast über medizinische Themen mit pol... more

Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010-2019)

World Health Organization WHO (2020) C_WHO

Antimalarial drug resistance has emerged as a threat to global malaria control efforts, particularly in the Greater Mekong subregion. Drawing on data collected through more than 1000 therapeutic efficacy studies as well as molecular marker studies of Plasmodium falciparum drug resistance, the Report... more

National Guidelines for the Treatment of Malaria - 2019

South African Malaria Elimination Committee (SAMC) National Department of Health South Africa (2019) CC

These guidelines are based on the 3rd Edition of the WHO Guidelines (Published 2015) World Health Organization’s Guidelines for the treatment of malaria. Additional literature surveys have been undertaken. Factors that were considered in the choice of therapeutic options included effectiveness, sa... more

Download (139)

View PDF (189)

Therapeutics for Ebola virus disease
recommended

World Health Organization WHO (2022) C_WHO

The WHO Ebola Virus Disease (EVD) Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with EVD. Providing guidance that is comprehensive and holistic for the optimal care of patients with EVD throughout their il... more

Traitements contre la maladie à virus Ebola
recommended

Organisation Mondiale de la Santé OMS (2022) C_WHO

Cette première version des orientations evolutives relatives a la prise en charge clinique de la MVE contient quatre nouvelles recommandations concernant l’utilisation de traitements contre la MVE, y compris deux recommandations fortes en faveur de l’utilisation de thérapies à base d’antico... more

Download (108)

View PDF (165)

First meeting of the network on Buruli ulcer PCR laboratories in the WHO African Region Centre Pasteur du Cameroon, Yaoundé, 21–24 October 2019

World Health Organization WHO (2020) CC

Research to develop point-of-care tests is in progress. Treatment of Buruli ulcer comprises 8 weeks of combined antibiotics (rifampicin and clarithromycin). Complementary therapies such as wound care, skin graft and prevention of disability are needed in some cases to ensure full recovery. The targ... more

Download (286)

View PDF (384)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Asia-Pacific Consensus Statement on the Management of Peripheral Artery Disease

Abola, M. T. B.; Golledge, J.; Miyata, T. et al. Journal of Atherosclerosis and Thrombosis (2020) CC

Peripheral artery disease (PAD) is the most underdiagnosed, underestimated and undertreated of the atherosclerotic vascular diseases despite its poor prognosis. There may be racial or contextual differences in the Asia-Pacific region as to epidemiology, availability of diagnostic and therapeutic mod... more

Download (33)

View PDF (47)

Prevention and management of CVD in LMICs: why do ethnicity, culture, and context matter?

Anand, S.; Bradshaw, C.; Prabhakaran, D. BMC Medicine (2020) CC

Background Low- and middle-income countries now experience the highest prevalence and mortality rates of cardiovascular disease. Main text While improving the availability and delivery of proven, effective therapies will no doubt mitigate this burden, we posit that studies evaluating cardiovasc... more

Leitfaden zum sensibilisierten Umgang mit Patient*innen

Sara Grzybek Queermed Deutschland (2024) CC

Diskriminierungssensibler Umgang mit Patient*innen ermöglicht allen Menschen gesundheitliche Hilfe aufzusuchen. Im Gesundheitssystem gibt es Menschen, die weniger sichtbar sind als andere. Damit sich Ärzt*innen, Therapeut*innen, Pflegende und andere im Gesundheitssystem Tätige stärker mit indiv... more

"Heile Welt" Podcast recommended

Therapeutics for Ebola virus disease recommended

Traitements contre la maladie à virus Ebola recommended

"Heile Welt" Podcast
recommended

Therapeutics for Ebola virus disease
recommended

Traitements contre la maladie à virus Ebola
recommended